These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30102538)

  • 1. Metalloporphyrin-Catalyzed Oxidation of Sunitinib and Pazopanib, Two Anticancer Tyrosine Kinase Inhibitors: Evidence for New Potentially Toxic Metabolites.
    Paludetto MN; Bijani C; Puisset F; Bernardes-Génisson V; Arellano C; Robert A
    J Med Chem; 2018 Sep; 61(17):7849-7860. PubMed ID: 30102538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions
    Paludetto MN; Stigliani JL; Robert A; Bernardes-Génisson V; Chatelut E; Puisset F; Arellano C
    Chem Res Toxicol; 2020 Jan; 33(1):181-190. PubMed ID: 31535851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes.
    Burns K; Nair PC; Rowland A; Mackenzie PI; Knights KM; Miners JO
    Drug Metab Dispos; 2015 Dec; 43(12):1934-7. PubMed ID: 26443648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.
    Shah RR; Morganroth J; Shah DR
    Drug Saf; 2013 Jul; 36(7):491-503. PubMed ID: 23620168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.
    Smith KS; Smith PL; Heady TN; Trugman JM; Harman WD; Macdonald TL
    Chem Res Toxicol; 2003 Feb; 16(2):123-8. PubMed ID: 12588182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib.
    Kongsuphon N; Soukavanitch M; Teeraaumpornpunt N; Konmun J; Ativitavas T; Ngamphaiboon N
    J Gastrointest Cancer; 2019 Sep; 50(3):601-603. PubMed ID: 29411249
    [No Abstract]   [Full Text] [Related]  

  • 7. Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review.
    Teo YL; Ho HK; Chan A
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):231-42. PubMed ID: 25400226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity.
    Sun Q; Zhu R; Foss FW; Macdonald TL
    Chem Res Toxicol; 2008 Mar; 21(3):711-9. PubMed ID: 18298092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.
    Klempner SJ; Choueiri TK; Yee E; Doyle LA; Schuppan D; Atkins MB
    J Clin Oncol; 2012 Sep; 30(27):e264-8. PubMed ID: 22802316
    [No Abstract]   [Full Text] [Related]  

  • 10. Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug-drug interactions and hepatotoxicity.
    Paludetto MN; Puisset F; Chatelut E; Arellano C
    Med Res Rev; 2019 Nov; 39(6):2105-2152. PubMed ID: 31111528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitor-induced immune hemolytic anemia; three different drugs in three separate cases.
    Güzel HG; Kıvrak Salim D
    J Oncol Pharm Pract; 2024 Jan; 30(1):215-219. PubMed ID: 37724017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic microsomal oxygenation of aldehydes to carboxylic acids.
    Watanabe K; Narimatsu S; Yamamoto I; Yoshimura H
    Biochem Biophys Res Commun; 1990 Feb; 166(3):1308-12. PubMed ID: 2306244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity Monitoring in Patients Treated with Tyrosine Kinase Inhibitors.
    Skubitz KM
    Oncologist; 2019 Jul; 24(7):e600-e602. PubMed ID: 30971480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.
    Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(4):626-630. PubMed ID: 30082547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatotoxicity of tyrosine kinase inhibitors: Mechanisms involved and practical implications].
    Béchade D; Chakiba C; Desjardin M; Bécouarn Y; Fonck M
    Bull Cancer; 2018 Mar; 105(3):290-298. PubMed ID: 29471963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating network pharmacology and drug side-effect data to explore mechanism of liver injury-induced by tyrosine kinase inhibitors.
    Tang M; Wu ZE; Li F
    Comput Biol Med; 2024 Mar; 170():108040. PubMed ID: 38308871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-Biphenylaldehyde and 9-anthraldehyde: two fluorescent substrates for determining P450 enzyme activities in rat and human.
    Marini S; Grasso E; Longo V; Puccini P; Riccardi B; Gervasi PG
    Xenobiotica; 2003 Jan; 33(1):1-11. PubMed ID: 12519690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
    Westerdijk K; Desar IME; Steeghs N; van der Graaf WTA; van Erp NP;
    Br J Clin Pharmacol; 2020 Feb; 86(2):258-273. PubMed ID: 31782166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
    Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
    Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism.
    Liu X; Lu Y; Guan X; Dong B; Chavan H; Wang J; Zhang Y; Krishnamurthy P; Li F
    Biochem Pharmacol; 2015 Sep; 97(1):111-21. PubMed ID: 26212543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.